Understanding the Market | Canoea-B Soars Over 6% Again, CM310 Has Submitted an IPO Application, Company Embraces a New Commercialization Cycle

Kanoya-B's stock price rose by over 6% to HKD 30.95, with a turnover of HKD 8.9888 million. The company owns a 70% stake in its non-wholly-owned subsidiary KYM and has reached a global exclusive licensing agreement with AstraZeneca to jointly develop and commercialize the product CMG901 (AZD0901). The company's core product CM310 has submitted an application for listing, with its treatment areas continuously expanding. CM310 is the fastest domestically developed IL-4Rα monoclonal antibody, having completed Phase III clinical trials for adult atopic dermatitis (AD). In addition, Phase III clinical studies for adolescent AD and seasonal allergic rhinitis have also been initiated for CM310. Furthermore, CMG901 (Claudin18.2-ADC) has made breakthroughs in the treatment of gastric cancer and gastroesophageal junction adenocarcinoma (G/GEJ). Kanoya-B's products demonstrate significant commercial potential